Navigation Links
t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application
Date:11/25/2008

FRANKFURT, Germany, November 25 /PRNewswire/ -- t2cure, a biopharmaceutical company developing regenerative medicine therapeutics from a patient's own stem cells, today announced that it has acquired a family of patents and patent applications from Innovectis, the technology transfer arm of Frankfurt University.

The patents cover a technology that allows for the rapid characterization of the potency of bone marrow-derived cells in the treatment of cardiovascular diseases. The potency of stem cells characterizes their potential to induce or perform repair processes in adult tissue. Recent drafts and guidelines from EMEA and FDA have made clear that potency testing will be a key criterion for batch release, and thus for market approval, of stem cell-based therapies.

"This acquisition of patent rights is a significant contribution to our regulatory strategy, as our lead product is advancing into a pivotal Phase III study in acute myocardial infarction," said Manfred Ruediger, CEO t2cure. "These patent rights complement our existing IP portfolio, supporting our commitment to make stem cell-based therapeutics a clinical reality for patients suffering from an acute heart attack or chronic heart failure."

Each year, 40,000 patients are hit by a severe heart attack in Germany alone and many more are suffering from chronic heart disease. Currently there is no treatment available that can reverse the damage to diseased heart muscle. In clinical trials, stem cell-based therapies under development by t2cure have demonstrated the potential to repair damaged tissue.

t2cure will use its technology for potency testing to confirm product specifications in the course of its upcoming pivotal Phase III study in acute myocardial infarction. This study, which will enroll up to 1,400 patients, is scheduled to enroll its first patients in the second quarter of 2009.

About t2cure GmbH

t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular disease including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease, non-ischemic heart failure, peripheral arterial occlusive disease, and diabetic polyneuropathy). The most advanced project (t2c001-AMI) has successfully passed Phase II of clinical development and is now prepared to enter Phase III. t2cure is privately financed with Entrepreneurs Fund BV, Amsterdam as lead investor.

    Contact

    Manfred Ruediger, CEO
    t2cure GmbH
    Bettinastrasse 35-37
    D-60325 Frankfurt am Main
    Tel: +49-69-75-61-46-87-0
    Fax: +49-69-75-61-46-87-9
    Email: info@t2cure.com
   http://www.t2cure.com


'/>"/>
SOURCE t2cure GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
2. BMP Sunstone Acquires Runchang Capsule and Related LFHC Technology
3. Vyta Corp Acquires 100% Ownership of BIOAGRA, LLC
4. Affitech Acquires Pharmexas Diabody Technology
5. Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity
6. CPA Acquires Renowned German Patent Research Specialist, SVPG
7. Circassia Acquires North American and Japanese Rights to Dopexamine
8. Advanced Instruments Acquires D & F Control Systems Inc.
9. Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations
10. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
11. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 24, 2017 Demonstrating its ongoing ... in Lehighton, Pennsylvania has now ... LLC ( www.prairiedogtech.com ). THE OBSERVER is a system ... endoscopes. The system ensures 100% compliance with safety best ... the challenge of preventing the growth and spread of ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... its award-winning CERF ELN (Electronic Laboratory Notebook) and Electronic Document ... manager used by laboratories, regulated scientific companies and biomedical organizations. CERF replaces ...
(Date:1/24/2017)... LANSING, Mich. , Jan. 24, 2017  Neogen ... it had terminated its agreement with SenesTech Incorporated (NASDAQ: ... marketing of a rodenticide being developed by SenesTech. The ... to the time when the SenesTech product was approved ... final EPA approval provided that the product could only ...
(Date:1/24/2017)... January 24, 2017 According to a new market ... Cell Counting, Cell Line Development, Flow Cytometry, Single-Use Bioprocessing, Biologics Safety Testing, ... by MarketsandMarkets, the global market is expected to reach USD 71.03 Billion ... 12.4% from 2016 to 2021. Continue Reading ... ...
Breaking Biology Technology:
(Date:1/12/2017)... DIEGO , Jan. 12, 2017  Trovagene, Inc. ... tumor DNA (ctDNA) technologies, today announced that it has ... Europe and the Middle East ... tests.  This milestone marks the first wave of international ... for urine and blood samples. The initial ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... of attendees at this year,s International Consumer Electronics Show (CES), A&D ... and services, will be featuring its new line of ULTRA CONNECT ... CES Exhibit Suite , the new upper arm and wrist smart blood ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):